Wei Zhu

Title: Innovations by Wei Zhu in Liquid Biopsy Technology

Introduction

Wei Zhu is an accomplished inventor based in Naperville, IL (US), known for his significant contributions to the field of liquid biopsy technology. With a total of 3 patents, he has developed innovative methods and systems that enhance the accuracy and reliability of cancer diagnostics.

Latest Patents

Wei Zhu's latest patents include groundbreaking work on methods and systems for dynamic variant thresholding in a liquid biopsy assay. This invention provides a comprehensive approach for validating somatic sequence variants in subjects with cancer conditions. By obtaining sequence reads from cell-free DNA fragments, the system aligns these reads to a reference sequence and identifies variant allele fragment counts. The comparison against a dynamic variant count threshold allows for the validation or rejection of the somatic sequence variant based on statistical analysis.

Another notable patent focuses on refining copy number variation in a liquid biopsy assay. This method involves obtaining a first dataset that includes bin-level sequence ratios and segment-level measures of dispersion. By applying various filters to this dataset, the system can validate or reject copy number status annotations for segments of the genome, thereby improving the accuracy of cancer diagnostics.

Career Highlights

Wei Zhu is currently employed at Tempus Labs, Inc., where he continues to innovate in the field of genomic medicine. His work is pivotal in advancing the capabilities of liquid biopsy assays, which are essential for non-invasive cancer detection and monitoring.

Collaborations

Throughout his career, Wei has collaborated with notable colleagues, including Terri M Driessen and Robert Tell. These partnerships have contributed to the development of cutting-edge technologies in the medical field.

Conclusion

Wei Zhu's contributions to liquid biopsy technology exemplify the impact of innovative thinking in the medical diagnostics industry. His patents not only enhance the understanding of cancer genomics but also pave the way for more effective patient care.